XNAS
QNTM
Market cap20mUSD
Oct 08, Last price
3.11USD
1D
-1.11%
1Q
-6.04%
IPO
-99.72%
Name
FSD Pharma Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
77.73%
Rev. gr., 5y
69.97%
Revenues
0
Net income
-26m
L+84.30%
CFO
-8m
L+21.88%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
FSD Pharma Inc. functions as a biotechnology firm dedicated to the discovery and advancement of pharmaceutical products. Its main drug candidate, FSD201, is a palmitoylethanolamide currently undergoing development for addressing inflammatory conditions. Furthermore, the company is pursuing research and development into Lucid-Psych, a molecular compound targeting mental health challenges, and Lucid-MS, another molecular compound designed for neurodegenerative illnesses. FSD Pharma Inc. maintains its corporate headquarters in Toronto, Canada.
Key people
Shahzad Shah
Chief Operating Officer of FV Pharma · since 2020
Interim Chief Financial Officer, Director · since 2018
Zeeshan Saeed
President, Director · since 2018
Robert J. Ciaruffoli
Independent Director · since 2019
James Anthony Datin
Independent Director · since 2019
Independent Director · since 2018
Headquarters & legal address
243 College Street, 101
Toronto, ON M5T 1R5
CA
Toronto, ON M5T 1R5
CA
Previous name
CENTURY FINANCIAL CAPITAL GROUP INC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||